News & Events

Redbiotec has expanded its platform by adding further microorganisms. In order to express proteins and small molecules at high yield, among other for the manufacturing of products in the food industry, Redbiotec has implemented yeast and bifidobacteria.

Redbiotec AG has entered into a research collaboration and exclusive option agreement with a large-cap pharmaceutical company. The collaboration will leverage Redbiotec’s proprietary bacteria platform BRISPR^® for the targeted delivery of gene therapy cargos from the partner.

“Redbiotec’s bacteria hold great potential in overcoming the delivery hurdles faced by conventional vehicles, such as adeno-associated viruses (AAVs) and nanoparticles. It is our goal to empower promising gene therapies for unmet medical needs through safe and targeted delivery,” said Christian Schaub, CEO of Redbiotec. “We are very pleased with our first pharma partnership on the BRISPR^® platform. Together, we will push the boundaries and create a new class of genetic medicines.” 

Date:  Feb 6, 2020

Location: Zürich

We will attend this year’s Swiss Nordic Bio Conference, and look forward to sharing the latest progress with our innovative bacteria-based delivery platform for gene therapies.

We thank you for your trust and support in 2019 and we wish you all the best in the forthcoming year! Best wishes, Christian Schaub, CEO, on behalf of the Redbiotec Team.

2020 marks an exciting year ahead for Redbiotec as the team gears up for more milestones. New partnerships and investment in growth will be essential pillars towards achieving our vision.